A phase 3 pivotal study of PXL01 for the prevention of patients undergoing tendon repair surgery.

Trial Profile

A phase 3 pivotal study of PXL01 for the prevention of patients undergoing tendon repair surgery.

Planning
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs PXL 01 (Primary)
  • Indications Post-surgical adhesions
  • Focus Registrational; Therapeutic Use
  • Sponsors ProMore Pharma
  • Most Recent Events

    • 01 Feb 2018 According to a ProMore Pharma media release, this and another phase 3 trial CTP700276926 will form the basis for market authorization in the US and Canada.
    • 22 Jan 2018 New trial record
    • 02 Jan 2018 According to a ProMore Pharma media release, company is preparing to submit an IND to the US Food and Drug Administration in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top